Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06071260
Other study ID # Atropine2023-2
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date December 20, 2023

Study information

Verified date October 2023
Source He Eye Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This aims to investigated the short-term (12, 16, and 20 h) effects of 0.01% atropine (0.1 mg/ml) on pupil size and subjective quality of vision in participants with myopia. Particpants will receive 0.01% atropine one drop to both eyes before bedtime. Baseline parameters were measured before atropine application. Changes in pupil sizes, under photopic and mesopic conditions, high-order aberration, and tear meniscus height were observed over the next day (12, 16, and 20 h).


Description:

The utilisation of atropine drops is a common practise in order to induce pupil dilatation, impede accommodation, and decelerate the advancement of myopia. Research findings indicate that the treatment of atropine at a low concentration of 0.01% has been observed to effectively slow down the advancement of myopia, with a reduction rate ranging from 60% to 83%. The administration of a lesser dose of atropine demonstrates a decreased occurrence of undesirable effects in comparison to the administration of atropine at a high concentration of 1.0%. Nevertheless, it is crucial to acknowledge that even when present in low concentrations, atropine still exerts an influence on both pupil size and pupil responsiveness. This investigation employs a prospective cohort study design, in which a set of objective and subjective assessments will be carried out before and after the injection of 0.01% atropine for a duration of 18 hours. The main aim of this study is to determine the effects of a specific concentration of atropine on several factors, including: 1) visual acuity; 2) pupil diameter; 3) subjective perception of vision quality; and 4) intraocular pressure. The objective of this study is to examine the effects of the eye drops on ocular health and determine the degree of patient acceptance about their prospective use as a preventive measure for myopia. The researchers have a positive expectation that the administration of the drops will have minimal influence on the participants in terms of side effects. However, the outcomes of this study will provide valuable insights for children and patients in effectively managing the side effects associated with the use of atropine for myopia control.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date December 20, 2023
Est. primary completion date December 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Diagnosed with myopia - Able to read and comprehend Chinese and willing to give informed consent as demonstrated by signing a record of informed consent. - Be between 18 and 60 years old, male or female. - Willing to apply eye drops once nightly at bedtime for one time and follow the clinical trial visit schedule as directed by the Investigator. - Willing to answer the questionnaire about subjective measurements. - Have ocular findings deemed to be myopic. - No history of wearing contact lens. - Vision correctable to at least 20/25 or better in each eye with spectacles. Exclusion Criteria: - Any pre-existing ocular irritation, injury or condition, including infection or disease. - Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. - - Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants. - Use of or a need for concurrent ocular medication at enrolment and/or during the clinical trial. - Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. - History of eye surgery - History of use of any myopia control interventions such as Orthokeratology, Rigid Permeable Contact Lenses Eye surgery within 12 weeks immediately prior to enrolment for this trial. - Currently treated with other interventions for myopia control - Contraindications to atropine such as pulmonary disease, heart conditions and ADHD - Known allergy or intolerance to ingredients to atropine eye-drops and other derivatives of anti-muscarinic receptor agents. - Currently enrolled in another clinical trial. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
0.01% atropine eye drop
One drop of 0.01% atropine will be administered to both eyes before bedtime. Baseline parameters were measured before and after atropine application.

Locations

Country Name City State
China He Eye Hospital Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
He Eye Hospital

Country where clinical trial is conducted

China, 

References & Publications (5)

Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-399. doi: 10.1016/j.ophtha.2015.07.004. Epub 2015 Aug 11. — View Citation

Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci. 2013 Dec;90(12):1467-72. doi: 10.1097/OPX.0000000000000037. — View Citation

Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, Wong TY, Naduvilath TJ, Resnikoff S. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-42. doi: 10.1016/j.ophtha.2016.01.006. Epub 2016 Feb 11. — View Citation

Polling JR, Kok RG, Tideman JW, Meskat B, Klaver CC. Effectiveness study of atropine for progressive myopia in Europeans. Eye (Lond). 2016 Jul;30(7):998-1004. doi: 10.1038/eye.2016.78. Epub 2016 Apr 22. — View Citation

Sankaridurg PR, Holden BA. Practical applications to modify and control the development of ametropia. Eye (Lond). 2014 Feb;28(2):134-41. doi: 10.1038/eye.2013.255. Epub 2013 Dec 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in pupil size Pupil size will be recorded before and after the administration of 0.01% atropine eye drop using the OPD-Scan III (NEIDEK, Japan) device. Baseline (before 0.01% atropine eye drop), 12 hours, 16 hours, and 20 hours.
Secondary Change in subjective quality of vision Subjective quality of vision will be recorded before and after the administration of 0.01% atropine eye drop. Baseline (before 0.01% atropine eye drop), 12 hours, 16 hours, and 20 hours.
Secondary Change in high-order aberration Change in high-order aberration will be recorded before and after administering 0.01% atropine eye drop using the OPD-Scan III (NEIDEK, Japan) device. Baseline (before 0.01% atropine eye drop), 12 hours, 16 hours, and 20 hours.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05919654 - Clinical Evaluation of MyoCare in Europe (CEME) N/A
Recruiting NCT03402100 - Eye Drops Study for Myopia Control in Schoolchildren N/A
Recruiting NCT03865160 - Low-dose Atropine for Myopia Control in Children Phase 2/Phase 3
Recruiting NCT06088225 - Myopia Preventing With Distance-image Screen N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Not yet recruiting NCT06405711 - To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia N/A
Recruiting NCT05881655 - Slow Myopia Progression With Different Irradiance Light N/A
Recruiting NCT05761379 - Clinical Study of Light Therapy to Control Myopia Progression in Children N/A
Not yet recruiting NCT05760911 - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches N/A
Recruiting NCT04722874 - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control N/A
Not yet recruiting NCT06221592 - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses N/A
Completed NCT04806711 - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children N/A
Completed NCT04806763 - Myopia Control With Orthokeratology Contact Lenses in Spain N/A
Completed NCT04806698 - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia N/A
Recruiting NCT05894382 - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control N/A
Completed NCT05683535 - Adverse Events Related to Low Dose Atropine
Completed NCT05300321 - DIMS-myopia Progression ADN Axial Length Growth N/A
Withdrawn NCT03519490 - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? N/A
Completed NCT05372991 - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop Phase 1/Phase 2
Active, not recruiting NCT05373693 - Myopia-control Efficacy by Peripheral Defocus Lens (PDL) N/A